You are being forwarded to your requested URL of https://sle.cooley.com/2022/06/06/in-re-nektar-therapeutics-ninth-circuit-affirms-dismissal-of-securities-class-action-arising-from-failure-of-clinical-drug-trial/?utm_source=mondaq&utm_medium=syndication&utm_content=sourceoriginal&utm_campaign=